ESTRIOL, ESTRADIOL, ESTRONE, AND PROGESTERONE IN COSMETIC PRODUCTS 127 use of therapeutically signifi cant levels (3%) of estrogen and related substances in cos- metic products. The agency is continuing to evaluate new data on this complicated issue to monitor the safety of these products, but to date, has found no convincing evidence that the ingredients used in such products pose a health risk to consumers. REFERENCES (1) M. A. Farage, S. Neill, and A. B. MacLean, Physiological changes associated with the menstrual cycle, A review, Obstet. Gynecol. Surv., 64, 58–72 (2009). (2) H. A. Zacur, Hormonal changes throughout life in women, Headache, 46 (Suppl), S50–S55 (2006). (3) F. Z. Stanczyk, J. P. Hapgood, S. Winer, and D. R. Mishell, Progestogens used in postmenopausal hor- mone therapy: Differences in their pharmacological properties, intracellular actions, and clinical effects, Endocr. Rev., 34, 171–208 (2013). (4) G. Hall, T. and J. Philips, Estrogen and skin: The effects of estrogen, menopause, and hormone replace- ment therapy on the skin, J. Am. Acad. Dermatol., 53, 555–568 (2005). (5) N. J. Raine-Fenning, M. P. Brincat, and Y. Muscat-Baron, Skin aging and menopause, Am. J. Clin. Dermatol., 4, 371–378 (2003). (6) P. G. Sator, J. B. Schmidt, T. Rabe, and C. C. Zouboulis, Skin aging and sex hormones in women— clinical perspectives for intervention by hormone replacement therapy, Exp. Dermatol., 13 (Suppl 4), 36–40 (2004). (7) S. Verdier-Sevrain, Effect of estrogens on skin aging and the potential of selective estrogen receptor modulators, Climacteric, 10, 289–297 (2007). (8) M. P. Brincat, Y. M. Baron, and R. Galea, Estrogens and the skin, Climacteric, 8, 110–123 (2005). (9) A. V. D. Sauerbronn, A. M. Fonseca, V. R. Bagnoli, P.H. Saldiva, and J. A. Pinotti, The effects of sys- temic hormone replacement therapy on the skin of postmenopausal women, Int. J. Gynecol. Obstet., 68, 35–41 (2000). (10) P. G. Sator, J. B. Schmidt, M. O. Sator, J. C. Huber, and H. Honigsmann, The infl uence of hormone replacement therapy on skin aging: A pilot study, Maturitas, 39, 43–55 (2001). (11) M. G. Shah and H. I. Maibach, Estrogen and the skin: an overview, Am. J. Clin. Dermatol., 2, 143–150 (2001). (12) J. F. Rossouw, G. L. Anderson, and R. L. Prentice, Risks and benefi ts of estrogen plus progestin in healthy post menopausal women: Principal results from the Women’s Health Initiative randomized controlled trial, JAMA, 288, 321–333 (2002). (13) D. Grady, D. Herrington, V. Bittner, Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up, JAMA, 288, 49–57 (2002). (14) M. Donovan, C. M. Tiwary, D. Axelrod, A. J. Sasco, L. Jones, R. Hajek, E. Sauber, J. Kuo, and D. L. Davis, Personal care products that contain estrogens or xenoestrogens may increase breast cancer risk, Med. Hypotheses, 68, 756–766 (2007). (15) P. D. Darbre, Environmental estrogens, cosmetics and breast cancer, Best Pract. Res, Clin. Endocrinol. Metab., 20, 121–143 (2006). (16) A. C. Hermann, A. N. Nafziger, J. Victory, R. Kulaway, M. L. Rocci, and J. S. Bertino, Over-the- counter progesterone cream produces signifi cant drug exposure compared to a Food and Drug Admin- istration approved oral progesterone product, J. Clin. Pharmacol., 45, 614–619 (2005). (17) A. C. Olson, J. S. Link, and T. C. Kupiee, Breast cancer patients unknowingly dosing themselves with estrogen using topical moisturizers, Cancer Res., 69 (Suppl 2), 4087–4088 (2009). (18) A. C. Olson, J. S. Link, J. R. Waisman, and T. C. Kupiee, Breast cancer patients unknowingly dosing themselves with estrogen using topical moisturizers, J. Clin. Oncol., 27, e103–e104 (2009). (19) S. Komori, Y. Ito, Y. Nakamura, M. Aoki, T. Takashi, T. Kinuta, H. Tanaka, and K. Koyama, A long- term user of cosmetic cream containing estrogen developed breast cancer and endometrial hyperplasia, Menopause, 15, 1191–1192 (2008). (20) Food and Drug Administration, Topically applied hormone-containing drug products for over-the- counter human use Final Rule, Federal Register, 58, 47608 (1993). (21) Food and Drug Administration, Summary of Regulatory Requirements for Labeling of Cosmetics Marketed in the United States: Cosmetics That Are Also Drugs (from the Cosmetic Labeling Manual, October 1991), http://www.cfsan.fda.gov/~dms/cos-lab1.html.

JOURNAL OF COSMETIC SCIENCE 128 (22) Cosmetic Ingredient Review Expert Panel, Final report on the amended safety assessment of Dioscorea villosa (wild yam) root extract, Int. J. Toxicol., 23 (Suppl 2), 49–54 (2004). (23) L. Havlikova, L. Novakova, L. Matysova, J. Sicha, and P. Solich, Determination of estradiol and its degradation products by liquid chromatography, J. Chromatogr., A, 1119, 216–223 (2006). (24) Y. Wen, Y. Wang, B. -S. Zhou, Y. Xu, and Y. -Q. Feng, Determination of sexual hormones in liquid cosmetics by polymer monolith microextraction couples with high performance liquid chromatography, Chin. J. Anal. Chem., 35, 681–684 (2007). (25) D. de Orsi, M. Pellegrini, S. Pichini, D. Mattioli, E. Marchei, and L. Gagliardi, High-performance liquid chromatography-diode array and electrospray-mass spectrometry analysis of non-allowed sub- stances in cosmetic products for preventing hair loss and other hormone-dependent skin diseases, J. Pharm. Biomed. Anal., 48, 641–648 (2008). (26) L. Novakova, P. Solich, L. Matysova, J. Sicha, HPLC Determination of estradiol, its degradation prod- uct, and preservatives in new topical formulation Estrogel HBF, Anal. Bioanal. Chem., 379, 781–787 (2004). (27) L. Wang, Y. -Q. Cai, B. He, C. -G. Yuan, D. -Z. Shen, J. Shao, and G. -B. Jiang, Determinations of estrogens in water by HPLC-UV using cloud point extraction, Talanta, 70, 47–51 (2006). (28) M. J. Lopez de Alda and D. Barcelo, Determination of steroid sex hormones and related synthetic com- pounds considered as endocrine disrupters in water by fully automated on-line solid-phase extraction liquid chromatography-diode array detection, J. Chromatogr., A, 911, 203–210 (2001). (29) M. J. Lopez de Alda and D. Barcelo, Determination of steroid sex hormones and related synthetic com- pounds considered as endocrine disrupters in water by liquid chromatography-diode array detection, J. Chromatogr. A, 892, 391–406 (2000). (30) L. Sun, W. Yong, X. Chu, and J. -M. Lin, Simultaneous determination of 15 steroidal oral contracep- tives in water using solid-phase disk extraction followed by high performance liquid chromatography- tandem mass spectrometry, J. Chromatogr. A, 1216, 5416–5423 (2009). (31) E. Vulliet, L. Wiest. R. Baudot, and M. -F. Genier-Loustalot, Multi-residue analysis of steroids at sub- ng/L levels in surface and ground-waters using liquid chromatography coupled to tandem mass spec- trometery, J. Chromatogr. A, 1210, 84–91 (2008).